Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study
Authors' conclusion
A specific combination of clinical/analytical/molecular variables was found to be associated with tumor invasiveness and growth capacity in GHomas. Pre-treatment with first-line drugs for acromegaly did not significantly modify the expression of the most relevant biomarkers in our association model. These findings provide valuable insights for risk stratification and personalized management of GHomas.
Study context
- Population
- Patients with growth hormone (GH)-secreting pituitary tumors (GHomas) from the REMAH study of the Spanish Society of Endocrinology and Nutrition
- Participants
- 192 patients
- Outcome
- Clinical/hormonal/molecular biomarkers associated with tumor size and invasiveness in GHomas
Main finding
As reported in the abstract
- Macroadenomas
- Eighty percent
- With extrasellar growth
- 63.8%
- Higher GH1 and lower PRL/POMC/CGA/AVPR1B/DRD2T/DRD2L expression associated with tumor invasiveness
- P < .05
- LASSO penalized regression: combinations of clinical and molecular features, AUC
- 0.67 and 0.82
Observational data: associations, not effects.
Further findings
Effect of pre-operative DA or SSA therapy on marker expression
- Pre-operative DA or SSAs did not alter expression of any marker analysed except DRD1/AVPR1B (up-regulated with DA) and FSHB/CRHR1 (down-regulated with SSAs)
Original publication
Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study. Eur J Endocrinol. Published 3 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →